Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
Featured trial
To Evaluate the Safety and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.  

The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal hepatic function and participants with hepatic impairment.

  • 0 views
  • 10 Sep, 2024
  • 3 locations
Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment

Study to Evaluate Pharmacokinetics and Safety of SHR0302 in Patients With Mild, Moderate Hepatic Impairment and Normal Liver Function in Phase I Clinical Study

moderate hepatic impairment
body mass index
moderate hepatic insufficiency
hepatic impairment
liver disease
  • 0 views
  • 16 Feb, 2024
  • 1 location
Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

The pharmacokinetics of a single dose of pexidartinib will be investigated in participants with impaired hepatic function and compared with healthy control participants with normal hepatic function.

  • 0 views
  • 16 Feb, 2024
  • 2 locations
Study to Evaluate the Pharmacokinetics (PK) of E7090 and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

The primary purpose of the study is to evaluate the effects of mild and moderate hepatic impairment on PK of E7090 after a single dose administration.

moderate hepatic impairment
electrocardiogram (ecg)
body mass index
moderate hepatic insufficiency
hepatic impairment
  • 0 views
  • 16 Feb, 2024
  • 3 locations
The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics

This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the effect of moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of aprocitentan (ACT-132577).

ovarian failure
systolic blood pressure
bilateral salpingectomy
kidney function tests
renal function
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies

This is a phase 1, 2-part, global, multicenter, open-label, PK, safety and tolerability study of oral tazemetostat in subjects with either advanced solid tumors, or hematological malignancies and normal hepatic function or moderate, or severe hepatic impairment.

hemolysis
major surgery
malabsorption
HIV Infection
opportunistic infection
  • 0 views
  • 16 Feb, 2024
  • 5 locations